Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Psilocybin Mushrooms

From Mazatec Ceremony to the Clinical Frontier

Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.

After a roughly 50-year research freeze, psilocybin has become one of the most promising areas in psychiatry. The US FDA granted it Breakthrough Therapy designation for treatment-resistant and major depression (2018-2019), reflecting strong preliminary trial evidence, and 2025 trials reported benefit for PTSD. Research also suggests efficacy for alcohol and tobacco use disorders, and for end-of-life anxiety. Importantly, the benefit appears tied to the supported, ritualized experience itself, a striking modern echo of the ceremonial context Indigenous traditions always insisted on. It remains investigational, not FDA-approved as a general medicine, and effects depend heavily on dose, set, and setting.

Reference only. Not medical advice.

What can go wrong

Psilocybin has low physiological toxicity and is not considered addictive, but the psychological risks are real: frightening or overwhelming experiences, lasting distress, and the potential to trigger or worsen psychosis or mania, especially in people with or at risk for bipolar or psychotic disorders. Unsupervised use can lead to dangerous behavior, and wild mushrooms are easily misidentified for poisonous or deadly look-alikes. In trials, benefit appears only with careful screening, preparation, and supervision. This entry documents the tradition and the research and is not a how-to or guidance to self-treat. Anyone considering psilocybin for depression, addiction, or any mental health condition should consult a qualified clinician, and people who are pregnant, who have a personal or family history of psychosis or bipolar disorder, or who take serotonergic medication face particular risk. Psilocybin remains federally illegal (Schedule I) in the United States even where individual states have created regulated access.

Psilocybin is the active compound in more than 100 species of Psilocybe mushrooms used ceremonially for centuries by Indigenous peoples of Mesoamerica. In the body it converts to psilocin, which acts on serotonin 5-HT2A receptors. After roughly 50 years of prohibition froze the science, controlled trials returned in the 2000s and now include several double-blind studies in depression, treatment-resistant depression, and alcohol use disorder, plus a 2024 meta-analysis and a first positive phase 3 result in 2025. The findings are genuinely promising and genuinely contested: the psychedelic experience is so unmistakable that most participants know whether they got the drug, so expectancy may be inflating the numbers. It remains investigational, federally illegal in the United States, and is studied only with careful screening and supervision.

Sacred healing mushrooms of Mesoamerican peoples, frozen out of science for 50 years, now an FDA "breakthrough" candidate for depression and addiction, with the ceremony itself proving central.

How it is supposed to work

Psilocybin is converted in the body to psilocin, which acts on serotonin (5-HT2A) receptors, transiently reorganizing brain network activity. In therapy this is thought to create a window of psychological flexibility, often accompanied by a profound subjective/mystical experience, that, paired with skilled support, can shift entrenched patterns in depression and addiction.

What people get wrong

  • Often saidPsychedelic mushrooms are a modern recreational invention.

    ActuallyThey were used in supported healing and divination ceremonies by Mazatec and other Mesoamerican peoples for centuries, and the Mazatec called them the holy children. Modern clinical interest is a return to a very old practice, documented by ethnographers and confirmed in the historical record around Maria Sabina and Huautla de Jimenez.

  • Often saidPsilocybin is an approved medicine you can use to self-treat depression.

    ActuallyAs of 2026 no psilocybin product has FDA approval, and it remains a Schedule I substance under federal law. Benefit in the research appears only with screening, preparation, and supervision. Unsupervised use carries real psychological risk and can be dangerous for people prone to psychosis or mania. Anyone considering it for a mental health condition should speak with a qualified clinician.

  • Often saidThe trial results settle the question that psilocybin is a powerful antidepressant.

    ActuallyThe results are promising but confounded. Because the psychedelic experience is unmistakable, most participants correctly guess whether they received the drug, reported at 70 to 94 percent across trials. Reviewers including Muthukumaraswamy and colleagues argue this functional unblinding and the expectancy it creates may inflate the measured benefit, which is why the finding is described as a signal rather than settled.

Who profits, and who pushes back

  • US FDA

    endorsesBreakthrough Therapy designation

    Granted psilocybin Breakthrough Therapy status for treatment-resistant and major depression, signaling preliminary evidence of substantial improvement over existing therapies.

  • Psychedelic-therapy researchers

    championsClinical trialists

    Report meaningful, sometimes durable benefit for depression, end-of-life anxiety, and alcohol and tobacco use disorders when psilocybin is given with psychological support in controlled settings.

  • Mazatec and Indigenous voices

    caveatsTradition-bearers

    Hold the mushrooms as sacred healing within ceremony and community, and note the harm caused when the practice was extracted and commercialized without consent or context.

  • Psychiatric-safety consensus

    cautionsNational Network of Depression Centers task group

    Warn that commercial and media enthusiasm is outpacing guidelines, that psilocybin can trigger mania or psychosis in vulnerable people, and that it requires careful screening and supervision.

Where the research comes from

Share of published research by country of origin.
PlaceShare of published research
US states with legal/decriminalized access (growing)30%

How we got here

Psilocybe mushrooms were used in supported healing and divination ceremonies across Mesoamerica long before European contact, among Mazatec, Nahua, Zapotec, and other peoples, and the Mazatec called them niños santos, the holy children. The Nahuatl word teonanacatl, roughly flesh of the gods, appears in colonial-era accounts. Western awareness came through Maria Sabina (1894 to 1985), a Mazatec sabia and poet in Huautla de Jimenez, Oaxaca, who in 1955 led an all-night velada for the American banker and amateur mycologist R. Gordon Wasson. His 1957 Life magazine article, Seeking the Magic Mushroom, and his later book identified her and her village. Seekers descended on Huautla. Sabina was ostracized, her house was burned, and a Mazatec practice meant for healing the sick was disrupted, an early and painful case of extraction from a living tradition. Laboratory chemistry followed, prohibition arrived in 1970, and research resumed only in the 2000s.

  1. Pre-1500sPsilocybe mushrooms used in supported healing and divination ceremonies across Mesoamerica by Mazatec, Nahua, Zapotec and other peoples
  2. 1955Maria Sabina leads a velada for R. Gordon Wasson in Huautla de Jimenez, Oaxaca
  3. 1957Wasson's Life article Seeking the Magic Mushroom introduces the ceremony to a wide Western audience, beginning decades of harm to Sabina and her community
  4. 1970US Controlled Substances Act places psilocybin and psilocin in Schedule I, halting most research for roughly 50 years
  5. 2018-2019FDA grants Breakthrough Therapy designation to COMPASS (treatment-resistant depression) and to Usona Institute (major depressive disorder)
  6. 2020Davis and colleagues at Johns Hopkins publish a randomized trial of psilocybin-assisted therapy for major depression (JAMA Psychiatry)
  7. 2020-2022Oregon (Measure 109) and Colorado (Proposition 122) approve state-regulated adult access frameworks
  8. 2021Carhart-Harris and colleagues at Imperial College publish a psilocybin-versus-escitalopram trial in NEJM
  9. 2022-2023Bogenschutz alcohol use disorder trial (JAMA Psychiatry) and Raison/Usona single-dose depression trial (JAMA) report benefit versus active or placebo comparators
  10. 2024BMJ meta-analysis of 9 RCTs (n=436) reports a moderate-to-large pooled effect for depression
  11. 2025COMPASS reports a positive first phase 3 trial (COMP005, n=258) for treatment-resistant depression

How it is understood

Psilocybe mushrooms have been used ceremonially for healing and divination by Indigenous peoples of Mexico and Central America, the Mazatec, Nahuatl, Zapotec, Mixe, and others, for many centuries, possibly far longer. In Mazatec tradition the mushrooms (los niños santos, "the holy children") are taken in a nighttime healing vigil (velada) led by a curandero/a such as the famed Mazatec healer Maria Sabina, whose 1950s ceremonies, shared with an outside visitor, became the bridge that carried these mushrooms into Western awareness (with painful consequences for her community).

At a glance

Traditional use
Mazatec and other Mesoamerican healing ceremonies
FDA status
Breakthrough Therapy (depression); still investigational
Emerging uses
Depression, PTSD, alcohol/tobacco use disorder
US legal status
Schedule I federally; some state exceptions

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Psilocybin Mushrooms. A short entry is not a safe entry.

  • Cost and market. We have not documented what it sells for or who sells it.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • How it compares. We have not set it against the alternatives.
  • Children and teenagers. We have not checked what is known about younger people.
  • What people take it for. We have not catalogued the claims made for it.

Sources